INSPIRE NEWS

Inspire Newsroom

New Inspire study with Takeda Pharmaceuticals sheds light on rare neuromuscular diseases

A new Inspire study presented at IgNS 2023 sheds light on the challenges faced by patients with Multifocal Motor Neuropathy (MMN) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). In collaboration with Takeda Pharmaceuticals and leading experts, the study explores the patient journey, highlighting diagnostic challenges, treatment barriers, and unmet needs in education and care.

Read more

Inspire to host industry webinar on real-world evidence in rare disease on October 12

Join Inspire’s webinar, Bridging the Gap: Strategies for Patient-Centered Real-World Evidence in Rare Diseases, on October 12 at 11 a.m. ET. Hosted by Richard Tsai, MS, Senior VP of Real-World Evidence, the event features Takeda experts Megan Gower, PharmD, and Edward Chou, PhD. Explore challenges and strategies for leveraging patient-centered RWE to enhance drug development and rare disease research.

Read more

New Inspire study sheds light on short bowel syndrome through real-world data

Inspire’s latest study, presented at ICPE 2023, sheds light on the diagnostic journeys, treatment patterns, and healthcare utilization of short bowel syndrome (SBS) patients. By linking patient data with HIPAA-compliant medical and pharmacy claims, the study reveals prolonged reliance on parenteral nutrition and significant out-of-pocket costs. Insights from Inspire’s online community further emphasize the financial and quality-of-life impacts of SBS, providing valuable context for understanding patient needs and advancing care solutions.

Read more
Scroll to Top